Advanced search
Publication Cover
Pathology Volume 31, 1999 - Issue 4
Submit an article Journal homepage
4
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Broadsheet Number 53: Activated Protein C Resistance: Diagnosis and Clinical Management

Ross I. Baker Clinical Thrombosis Unit, Haematology Department, Royal Perth Hospital, University of Western Australia, Perth, Australia;
,
John Eikelboom The Preventive Cardiology and Therapeutics Program, McMaster University, Canada
&
Alison Street Haematology Department, Alfred Hospital, Melbourne, Australia
Pages 365-371 | Published online: 06 Jul 2009

  • Anderson FA, Wheeler HB. Venous thromboembolism: risk factors and prophylaxis. Clin Chest Med 1995; 16: 235-51.
  • Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C; Prediction of a cofactor to activated protein C. Proc Natl Acad Sei USA 1992; 90: 1004-8.
  • Zoller B, Dahlback B. Resistance to activated protein C caused by a factor V gene mutation. Curr Opin Hematol 1995; 2(5): 358-64.
  • Bertina RM, Reitsma PH, Rosendaal FR, Vandenbroucke JP. Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. Thromb Haemost 1995; 74: 449-53.
  • Svensson P, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. New Engl J Med 1994; 330: 517-22.
  • Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
  • Voorberg J, Roelse J, Koopman R, et al. Association of idiopathic venous thromboembolism with single point mutation at Arg306 of factor V. Lancet 1994; 343: 1535-6.
  • Beufe S, Borg J, Vasse M, et al. Co-segregaton of thrombosis with factor V Q306 mutation in an extended family with resistance to activated protein C. Br J Haematol 1995; 89: 659-62.
  • Zoller B, Dahlback B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994; 343: 1536-8.
  • Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 1994; 269: 31869-80.
  • van Bockxmeer F, Baker RI, Taylor RR. Premature ischaemic heart disease and the gene for coagulation factor V. Nat Med 1995; 1: 185.
  • Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993; 8: 1989-93.
  • Koster T, Rosendaal FR, Ronde H de, et al. Venous thrombosis due to a poor anticoagulant response to activated protein C. Lancet 1993; 342: 1503-6.
  • Ridker PM, Miletich JP, Stampfer MJ, et al. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation, 1995; 92: 2800-2.
  • Eichinger S, Pabinger I, Stumpften A, et al. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost 1997; 77: 624-8.
  • Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-8.
  • Emmerich J, Alhenc-Gelas M, Aillaud M-F, et al. Clinical features in 36 patients homozygous for the ARC 506 -> GLN factor V mutation. Thromb Haemost 1997; 77: 620-3.
  • Vandenbroucke JP, Koster T, Briet E, et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7.
  • Hellgren M, Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995; 173: 210-213.
  • Bloemenkamp KWM, Rosendaal FR, Heimerhorst FM, et al. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a thirdgeneration progestagen. Lancet 1995; 346: 1593-6.
  • Farmer RD, Lawrenson RA, Thompson CR, et al. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997; 349: 83-8.
  • Ferez Gutthann S, Garcia Rodriguez LA, Castellsague J, Duque Oliart A. Hormone replacement therapy and the risk of venous thromboembolism: population-based case-control study. Br Med J 1997; 314: 796-800.
  • DaIy E, Vessey MP, Hawkins MM, Carson JL, et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 346: 977-80.
  • Bokarewa MI, Bremme K, Blomback M. Arg506 Gln mutation in factor V and risk of thrombosis during pregnancy. Br J Haematol 1996; 92: 473-8.
  • Andersen BS, Steifen sen FH, Sorensen HT, et al. The cumulative incidence of venous thromboembolism during pregnancy and puerperium: an 11 year Danish population-based study of 63,300 pregnancies. Acta Obstet Gynecol Scand 1998; 77: 170-3.
  • Denninger M, Beldjord K, Durand F, et al. Budd-Chiari syndrome and factor V Leiden mutation. Lancet 1995; 345: 525.
  • Martinelli I, Land! G. Merati G. et al. Factor V gene mutation is a risk factor for cerebral venous thrombosis. Thromb Haemost 1996; 75: 393-4.
  • Larsson J. Olafsdottir E. Bauer B. Activated protein C resistance in young adults with central retinal vein occlusion. Br J Ophthalmol 1996; 80: 200-2.
  • de Prost D. Delmas V, Lefebvre M. et al. Priapism revealing Arg506 to GIn factor V mutation, l Ural 1996; 155: 1392.
  • Gardyn J, Sorkin P, Kluger Y, et al. Heparin-induced thrombocytopenia and fatal thrombosis in a patient with activated protein C resistance. Am J Hematol 1995; 50: 292-5.
  • Makris M, Bardhan G. Preston FE. Warfarin induced skin necrosis associated with activated protein C resistance. Thromb Haemost 1996; 75: 523-4.
  • Bucalossi A, Marotta G, Bigazzi C, et al. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis. Am J Hematol 1996; 52: 14-9.
  • Rosendaal FR, Siscovick SM, Schwarte RK, et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997; 89: 2817-21.
  • Foley PW, Irvine CD, Standen GR, et al. Activated protein C resistance, factor V Leiden and peripheral vascular disease. Cardiovasc Surg 1997; 5: 157-60.
  • Ouriel K, Green RM, De Weese JA, Cimino C. Activated protein C resistance: prevalence and implications in peripheral vascular disease. J Vase Surg 1996; 23: 46-52.
  • Grandone E, Margaglione M, Calaizzo D, et al. Factor V Leiden is associated with repeated and unexplained foietal loss. Thromb Haemost 1997; 77: 822-4.
  • Lindoff C, Ingermarsson I, Martinsson G, et al. Preeclampsia is associated with a reduced response to activated protein C. Am J Obstet Gynecol 1997; 176: 457-60.
  • Grisaru D, Fait G, Eldor A. Activated protein C resistance and pregnancy complications. Am J Obstet Gynecol 1996; 174, 801-802.
  • Koeleman BPC, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C deficient families. Blood 1994; 84, 1031-5.
  • Koeleman BPC, van Rumpt D, Hamulyak K, et al. Factor V Leiden: An additional risk factor for thrombosis in protein S deficient families? Thromb Haemost 1995; 74: 580-3
  • Zoller B, Berntsdotter A, de Frutos PG, Dahlback D. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85: 3518-23.
  • van Boven HH, Reitsma PH, Rosendaal FR, et al. Factor V Leiden (FV R306Q) in families with inherited antithrombin deficiency. Thromb Haemost 1996; 75: 417-21.
  • Makris M, Preston FE, Beauchamp NJ, et al. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia. Thromb Haemost 1997; 78: 1426-9
  • Ridker PM, Hennekens CH, Selhub J, et al. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 1997; 96: 1777-82.
  • Jorquera JI, Montoro JM, Fernandez MA, et al. test for activated protein C resistance. Lancet 1994; 344: 1162-1163.
  • Hall CM, Andersseon NE, Andersson M, et al. Complete discrimination for FV: Q306 in plasma from OAC-patients, heparin patients and non-treated individuals using the COATEST APC resistance assay after predilution in V-DEF plasma. Blood Coagul Fibrinolysis 1996; 7 : 59.
  • Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3' untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-3703.
  • Sakata T, Kario K, Katayama Y, et al. Clinical significance of activated protein C resistance as a potential marker for hypercoagulable state. Thromb Res 1996; 82: 235-44.
  • Gumming AM, Tait RC, Fildes S, Hay CRM. Diagnosis of APC resistance during pregnancy. Br J Haematol 1996; 92: 1026-7.
  • Henkens CMA, Bom VJJ, Seinen AJ, van der Meer J. Sensitivity to activated protein C; influence of oral contraceptives and sex. Thromb Haemost 1995; 73: 402-4.
  • Matsuda J, Gotoh M, Gohchi K, et al. Resistance to activated protein C activity of an anti-ß2-glycoprotein I antibody in the presence of ß2-glycoprotein I. Br J Haematol 1995; 90: 204-6.
  • Gschwandtner ME, Eichinger S, Mutter D, et al. Lupus anticoagulant and thromboembolism: Evaluation of fibrinogen, natural inhibitors and molecular markers of thrombosis. Blood Coagul Fibrinolysis 1996; 7: 325-30.
  • van der Bom JG, Bots ML, Haverkate F, et al. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann Intern Med 1996; 125: 265-269.
  • Williamson D, Brown K, Luddington R, et al. Factor V Cambridge: a new mutation (Arg306-> Thr) associated with resistance to activated protein C. Blood 1998 Feb 15;91(4):1140-1144
  • Ireland H, Bayston T, Thompson E, et al. Apparent heterozygous type II protein C deficiency caused by the factor V506 Arg to GIn mutation. Thromb Haemost 1995: 731-2.
  • Faioni EM, Franchi F, Asti D, et al. Resistance to activated protein C in nine thrombophilic families: Interference in a protein S functional assay. Thromb Haemost 1993; 70: 1067-71.
  • de Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia:Pathogenesis, clinical syndromes, and management. Blood 1996; 87: 3531-44.
  • Faioni EM. Franchi F, Asti D. Mannucci PM. Resistance to activated protein C mimicking dysfunctional protein C: diagnostic approach. Blood Coagul Fibrinolysis 1996; 7: 349-51.
  • Svensson PJ, Benoni G, Fredin H, et al. Female gender and resistance to activated protein C (FV:Q506) as potential risk factors for thrombosis after elective hip surgery. Thromb Haemost 1997; 78: 993-6.
  • Rosendaal FR. Oral contraceptives and screening for Factor V Leiden. Thromb Haemost 1996; 75: 524-5.
  • HiIIe ETM, Westendorp RGJ. Vandenbroucke JP. Rosendaal FR. Mortality and causes of death in families with the factor V Leiden mutation (resistance to activated protein C). Blood 1997; 89: 1963-7.
  • Mari D, Mannucci PM. Duca F, et al. Mutation factor V (Arg306Gln) in healthy centenarians. Lancet 1996; 347: 1044.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.